Merck KGaA, Darmstadt, Germany
Frankfurter Straße 250
Darmstadt
64293
Germany
Tel: 49-6151-720
Fax: 49-6151-722000
Website: https://www.emdgroup.com/en
Email: service@emdgroup.com
509 articles with Merck KGaA, Darmstadt, Germany
-
BioSpace Movers & Shakers, Jan. 15
1/15/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers and Shakers. -
Merck KGaA buys Amptec for mRNA tech and Chimerix acquires Oncoceutics for cancer pipeline.
-
EMD Serono Appoints Manuel Zafra as New Managing Director for Canada
1/6/2021
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, is pleased to announce the appointment of Manuel Zafra as the new Managing Director for Canada.
-
BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
12/11/2020
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of BAVENCIO®
-
Artios and Merck KGaA announce global strategic collaboration
12/3/2020
Arix Bioscience plc (“Arix”, LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, notes that portfolio company Artios Pharma Limited (“Artios”), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, and Merck KGaA, Darmstadt, Germany (“Merck KGaA”)
-
Merck KGaA and Artios Pharma Limited announced today that they have entered a strategic collaboration agreement to discover and develop multiple precision oncology drugs over the course of the next three years.
-
Massachusetts-based Businesses of Merck KGaA, Darmstadt, Germany Named to The Boston Globe's 'Top Places to Work' List
11/20/2020
Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that its Massachusetts-based businesses, MilliporeSigma, EMD Serono and EMD Performance Materials, have again been named to The Boston Globe's annual "Top Places to Work 2020" list.
-
Merck KGaA, Darmstadt, Germany, to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on 19 November 2020
11/13/2020
Merck KGaA, Darmstadt, Germany (LOCAL EXCHANGE: Deutsche Börse, US EXCHANGE: OTC), a leading science and technology company, today announced that Merck KGaA, Darmstadt, Investor Relations Director llja Doering will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on November 19.
-
Merck KGaA, Darmstadt, Germany, Recognized for Collaborative Cancer Research by CEO Roundtable on Cancer
11/10/2020
The CEO Roundtable on Cancer has recognized the healthcare business of Merck KGaA, Darmstadt, Germany, operating as EMD Serono in the US and Canada, with the 2020 Dr. Charles A. Sanders Award for collaborative scientific research in cancer.
-
MAVENCLAD (cladribine tablets) is available through public drug plans for the majority of eligible Canadians with Relapsing-Remitting Multiple Sclerosis
10/27/2020
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, is pleased to announce that eligible patients have access to PrMAVENCLAD® (cladribine tablets) through seven provincial public drug plans including the Régie de l'assurance maladie du Québec (RAMQ) and the Ontario Drug Benefit Exceptional Access Program.
-
IAVI, Merck KGaA, Darmstadt, Germany, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
10/22/2020
Today, IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, and Serum Institute of India Pvt. Ltd., a leading manufacturer of vaccines and biologics, announced an agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to develop SARS-CoV-2 neutralizing monoclonal antibodies (mAbs) co-invented by IAVI and Scripps Research
-
Merck KGaA, Darmstadt, Germany, Announces Retirement of Luciano Rossetti, Global Head of R&D for Healthcare
10/15/2020
Merck KGaA, Darmstadt, Germany , a leading science and technology company, today announced that Dr. Luciano Rossetti, MD, will be retiring as Global Head of Research
-
Precigen Announces Merck KGaA, Darmstadt, Germany Increases Ownership Position Through Exercise of Convertible Note
10/9/2020
Precigen, Inc. (Nasdaq: PGEN), today announced that leading science and technology company and existing shareholder Merck KGaA, Darmstadt, Germany, through its wholly owned subsidiary, Ares Trading S.A., has elected to voluntarily convert a convertible note with an outstanding principal balance of $25 million
-
The German company announced that the new CEO will take the reins in May 2021.
-
BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine
9/18/2020
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study online ahead of print in The New England Journal of Medicine.
-
EMD Serono Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020
9/13/2020
New analyses from Phase III JAVELIN Bladder 100 study of BAVENCIO®* assess efficacy across subgroups, patient-reported outcomes and exploratory biomarkers in advanced urothelial cancer
-
Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA, Darmstadt, Germany for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
8/25/2020
Sutro Biopharma, Inc. announced that it has achieved a clinical supply milestone under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany and is entitled to receive a milestone payment.
-
Clinical Catch-Up: August 3-7
8/10/2020
It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look. -
Merck KGaA, Darmstadt, Germany Selects Cambridge Semantics as Enterprise Data Fabric Provider
7/16/2020
Cambridge Semantics Aiding Merck KGaA, Darmstadt, Germany in Modernizing its Data Integration Capabilities and in Forging Multiple Data-driven Initiatives BOSTON--( BUSINESS WIRE )-- Cambridge Semantics, the leading provider of modern, graph-driven data integration for the enterprise data fabric, today announced that Merck KGaA, Darmstadt, Germany and its US-based biopharmaceutical business EMD Serono, have selected Cambridge Semantics as its dat
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.